In the episode, hosts provide insight into sessions to watch, device news they are excited for, what makes ATTD a unique and valuable experience for the diabetes care team, and how the meeting’s annual yearbook session encapsulates the exciting developments within the field.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-attd-2024-preview 

Key Highlights: 
01:05 - Bellini’s ATTD Picks
03:45 - Isaacs’ ATTD Picks
06:20 - Health Disparities in Focus
07:10 - Time in Tighter Range
10:20 - Insulin Users with T2D
11:15 - ATTD Yearbook Session

The introduction of CGM in 1999 completely shifted the trajectory of care for people with diabetes. Now, new data suggest advanced CGM metrics, such as time in range, are proving comparable to HbA1c for predicting diabetic retinopathy and other microvascular outcomes.

In this episode, Viral Shah, MD, joins Diabetes Dialogue to discuss a recent study examining associations between time in range and other advanced CGM metrics with diabetic retinopathy and the implications for use in predicting other microvascular outcomes.

Episode Highlights

00:05 - Intro

02:04 - CGM Data to Predict Diabetes Complications

05:15 - Time in Range and Microvascular Complications

09:36 - Glycemic Variability and Incident Diabetic Retinopathy

12:17 - Time in Range, CGM Data for Predicting CV Outcomes

In this episode, hosts are joined by Shah for a discussion on his recent proof-of-concept study looking at tirzepatide in type 1 diabetes, the prospect of GLP-1 RA-based therapies in type 1 diabetes, and the potential roles for tirzepatide beyond T2D and weight management.

Episode Highlights
00:00 - Intro
01:56 - Use of GLP-1s in T1D
05:32 - Study on Tirzepatide in T1D 
10:04 - Insulin Use in Study
11:20 - Safety Outcomes

In this episode, hosts discuss recent news and updates in diabetes technology from Abbott, Dexcom, and Medtronic in the first half of January 2024.

Episode Highlights

00:40 Abbott FreeStyle Libre 2 Plus
18:08 Dexcom Stelo
26:30 Medtronic Simplera Sync

In this episode, hosts sit down with Ralph DeFronzo, MD, for a discussion on how advances in management have transformed the diagnosis and management of hypercortisolism among people with type 2 diabetes.

Episode Highlights

00:39 DeFronzo Introduction
01:54 Presentation of Hypercortisolism
05:50 Ominous Octet and Hypercortisolism
09:47 Prevalence of Hypercortisolism in T2D
13:57 Impact of Untreated Hypercortisolism
17:05 Screening for Hypercortisolism
21:25 CATALYST Trial
31:30 Outro

In this episode, the hosts break down a pair of recent studies published in JAMA examining use of non-insulin agents in the management of diabetes during pregnancy.

Episode Highlights
00:05 Intro
00:28 Episode Overview
02:00 GLP-1 RAs in Early Pregnancy
05:53 Implications of Results
10:30 Metformin in Early Pregnancy
13:48 Implications of Results

Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management.

Episode Highlights
00:05 Intro
01:20 Baricitinib Overview
02:30 BANDIT Trial Design
03:30 Trial Results
05:40 Delaying Type 1 Diabetes
14:45 Need for Screening
18:00 Outro

To celebrate the end of 2023, hosts recap the top 10 episodes of the past year and offer perspective on how the news discussed in these episodes has shaped the future of diabetes management.

Episode Highlights
00:32 Automated Insulin Delivery News in October 2023
04:35 Breaking Down AACE's New Type 2 Diabetes Management Algorithms
06:45 What Medicare Drug Price Negotiations Mean for Diabetes 
09:15 STEP-HFpEF Reaction 
12:10 Dexcom G7 and the Future of CGM, with Jake Leach
13:20 Tandem Mobi and Welldoc's BlueStar Platform
16:20 Making Sense of Semaglutide in Type 1 Diabetes
18:35 Establishing Time in Range as a Primary Glucose Metric
21:15 TRANSITION-T2D, with Paloma Rodriguez, MD, and Kevin Pantalone, DO 
25:15 What to Know about the iLet Bionic Pancreas

Hosts discuss what they consider the most significant or relevant updates in the ADA's Standards of Care—2024, with a focus on new recommendations for glycemic management, bone health, immunizations, and weight management. 

Episode Highlights

0:05 Intro
1:04 Glycemic Management Updates
9:00 Bone Health Updates
13:30 Immunization and Vaccination Updates
15:35 Weight Management Updates
23:10 Outro

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the latest in diabetes technology from December 2023, with a spotlight on announcements surrounding use of Dexcom’s G7 continuous glucose monitoring (CGM) system as well as the latest updates to the American Diabetes Association’s Standards of Care.

Episode Highlights

0:05 Intro
0:42 AID Integrations with Dexcom G7
7:02 ADA Standards of Care Updates
12:11 Diabetes and Pregnancy Updates
18:45 Artificial Intelligence in Retinopathy Screening
22:32 Outro